Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Olumiant ® (baricitinib) tabletter
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
Baricitinib Drug-Drug Interaction Study Results
The recommended dose is 2 mg once daily in patients taking Organic Anion Transporter 3 (OAT3) inhibitors with a strong inhibition potential, such as probenecid.1
Tofacitinib Drug-Drug Interaction Study Results
From the Xeljanz® EU summary of product characteristics
The recommended dose is tofacitinib 5 mg once daily in patients with RA and receiving
strong inhibitors of CYP3A4, or
one more concomitant medications that result in both moderate inhibition of CYP3A4 and strong inhibition of CYP2C19.2
Coadministration of strong inducers of CYP3A4 (eg, rifampin) with tofacitinib may result in loss of or reduced clinical response to tofacitinib. Coadministration of strong inducers of CYP3A4 with tofacitinib is not recommended.2
1. Olumiant [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2. Xeljanz [summary of product characteristics]. Pfizer Europe MA EEIG.
Glossary
BARI = baricitinib
CYP = cytochrome P450
OAT = organic anion transporter
RA = rheumatoid arthritis
US = United States
Xeljanz = Xeljanz® (tofacitinib)
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Datum fӧr senaste ӧversyn 2019 M07 26